What vaccine‑related adverse effect should be considered when a patient develops new‑onset petechiae, easy bruising, mucosal bleeding, or unexplained thrombocytopenia after immunization?

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)

When a patient develops new-onset petechiae, easy bruising, mucosal bleeding, or unexplained thrombocytopenia after immunization, you must immediately consider Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), a rare but potentially life-threatening adverse effect caused by anti-platelet factor 4 (PF4) antibodies that trigger intense platelet activation and coagulation system activation. 1

Critical Timing Window

VITT symptoms characteristically appear 5 to 30 days post-vaccination (up to 42 days for isolated DVT/PE). This timing is essential for diagnosis—symptoms occurring immediately after vaccination (within 2-3 days) such as injection site pain, fatigue, headache, and fever are common benign reactions unrelated to VITT. 1

Clinical Presentation Beyond Bleeding

While petechiae, bruising, and mucosal bleeding reflect the thrombocytopenic component, thrombosis is the dominant and most dangerous feature of VITT:

• Cerebral venous sinus thrombosis (CVST) occurs in 50% of cases, presenting as severe headache that worsens progressively, doesn't respond to simple analgesics, worsens when lying down or bending over, and may be accompanied by blurred vision, nausea, vomiting, speech difficulty, weakness, drowsiness, or seizures 1
• One-third of patients have thrombosis at multiple sites simultaneously 1
• Portal/splanchnic vein thrombosis presents with persistent abdominal pain
• Pulmonary embolism causes shortness of breath and chest pain
• Deep vein thrombosis manifests as leg swelling 1

Diagnostic Criteria

Definite VITT requires all five criteria 1:

• Symptom onset 5-30 days post COVID-19 vaccine
• Presence of thrombosis
• Thrombocytopenia (platelet count <150×10⁹/L)
• D-dimer >4000 μg/mL (FEU)
• Positive anti-PF4 antibodies by ELISA

Critical caveat: 5% of VITT patients have normal platelet counts initially that subsequently drop—repeat platelet count after 2-3 days if clinical suspicion remains high. 1

Immediate Management Algorithm

If Patient is Acutely Unwell:

Refer to emergency department immediately 1

If Patient is Stable:

1. Obtain same-day full blood count in primary care
2. If thrombocytopenia confirmed → immediate ED referral 1

In Secondary Care:

1. Order immediately:

   • D-dimer measurement
   • Coagulation screen with Clauss fibrinogen assay
   • Blood film to confirm true thrombocytopenia
   • Anti-PF4 antibody ELISA 1

2. Same-day imaging based on symptoms:

   • Head CT venogram or MRA for suspected CVST
   • Abdominal ultrasound/venogram for portal/splanchnic thrombosis
   • CT pulmonary angiography for PE
   • Duplex ultrasound for DVT 1

Treatment Protocol

Start treatment immediately upon high clinical suspicion—do not wait for confirmatory testing 1:

First-Line Therapy (All Suspected VITT):

• Intravenous immunoglobulin 1 g/kg to remove anti-PF4 antibodies, prevent platelet activation, and improve platelet count 1

For Confirmed Thrombosis:

• Therapeutic anticoagulation with non-heparin anticoagulants (avoid heparin due to cross-reactivity risk with heparin-induced thrombocytopenia)
• Options: argatroban, fondaparinux, danaparoid sodium, or direct oral anticoagulants 1
• Start as soon as possible after bleeding risk assessment 1

For Thrombocytopenia Without Confirmed Thrombosis:

• If D-dimer very high and anti-PF4 antibodies positive: consider VTE thromboprophylaxis with non-heparin agents 1

Additional Considerations:

• Add corticosteroids if IVIg insufficient 1
• Platelet transfusion or fibrinogen replacement if surgery needed and bleeding risk high 1
• Maintain fibrinogen ≥1.5 g/L 1

Epidemiology and Risk Factors

VITT is rare: 14.9 per million after first COVID-19 vaccine dose, 1.8 per million after second dose. Adults aged 18-49 years have twice the incidence rate compared to those ≥50 years. 1 Cases have been reported with both adenoviral vector vaccines 1, 2, 3 and mRNA vaccines 4, 5, 6, 7, as well as whole-virus vaccines 8.

Patients with pre-existing chronic ITP are at higher risk for exacerbation, particularly those who have undergone splenectomy or are on >5 medications. 9, 6

Critical Pitfall to Avoid

Never use heparin-based anticoagulation in suspected or confirmed VITT due to potential cross-reactivity with the pathogenic anti-PF4 antibodies, similar to heparin-induced thrombocytopenia. 1 This is a potentially fatal error.